Aclaris Therapeutics
ACRS
58 hedge funds and large institutions have $397M invested in Aclaris Therapeutics in 2016 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 4 closing their positions.
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
156% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 9
40% more capital invested
Capital invested by funds: $284M → $397M (+$114M)
26% more funds holding
Funds holding: 46 → 58 (+12)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$9.12M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$3.88M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$3.71M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.97M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$2.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$22.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.77M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$2.58M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$614K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$357K |
ACRS Hedge Fund Activity: Q3 2016 in Review
58 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2016, worth a combined $397M — up 40% from $284M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ACRS positions and 4 closed out — a net gain of 12 holders — while 23 added to existing stakes and 9 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $9.12M. The largest seller was RA Capital Management, cutting an estimated $22.9M.
- 58 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2016, up from 46 in Q2 2016.
- Funds reported $397M of Aclaris Therapeutics stock for Q3 2016, up 40% quarter-over-quarter.
- 16 funds opened new Aclaris Therapeutics positions in Q3 2016 and 4 closed out, a net change of +12 holders.
- The largest Aclaris Therapeutics buyer in Q3 2016 was Perceptive Advisors, an estimated $9.12M added.
- The largest Aclaris Therapeutics seller in Q3 2016 was RA Capital Management, an estimated $22.9M sold.
Based on aggregated 13F filings for Q3 2016.